The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy
Open accessAbstract
Purpose: Liver dissemination is a major cause of mortality among patients with advanced colorectal cancer. Hepatic intra-arterial injection of the β-emitting isotope yttrium-90 (90 Y) bound to resin microspheres (radioembolization) delivers therapeutic radiation doses to liver metastases with minimal damage to adjacent tissues. Patients and Methods: We conducted a prospective, multicenter, randomized phase III trial in patients with unresectable, chemotherapy-refractory liver-limited metastatic CRC (mCRC) comparing arm A (fluorouracil [FU] protracted intravenous infusion 300 mg/m 2 days 1 through 14 every 3 weeks) and arm B (radioembolization plus intravenous FU 225 mg/m 2 days 1 through 14 then 300 mg/m 2 days 1 through 14 every 3 weeks) until hepatic progression. The primary end point was time to liver progression (TTLP). Cross-over to radioembolization was permitted after progression in arm A. Results: Forty-six patients were randomly assigned and 44 were eligible for analysis (arm A, n = 23; arm B, n = 21). Median follow-up was 24.8 months. Median TTLP was 2.1 and 5.5 months in arms A and B, respectively (hazard ratio [HR] = 0.38; 95% CI, 0.20 to 0.72; P = .003). Median time to tumor progression (TTP) was 2.1 and 4.5 months, respectively (HR = 0.51; 95% CI, 0.28 to 0.94; P = .03). Grade 3 or 4 toxicities were recorded in six patients after FU monotherapy and in one patient after radioembolization plus FU treatment (P = .10). Twenty-five of 44 patients received further treatment after progression, including 10 patients in arm A who received radioembolization. Median overall survival was 7.3 and 10.0 months in arms A and B, respectively (HR = 0.92; 95% CI, 0.47 to 1.78; P = .80). Conclusion: Radioembolization with 90 Y-resin microspheres plus FU is well tolerated and significantly improves TTLP and TTP compared with FU alone. This procedure is a valid therapeutic option for chemotherapy-refractory liver-limited mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 1×
“Chemotherapy combined with biologic agents have improved mCRC median survival rates and rendered an increasing number of patients resectable.(3-10) However, the recurrent nature of mCRC, particularly in the liver, remains a life-limiting prognosis for the majority of patients with advanced disease.”
BackgroundSelf-citationNordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60455-9 · Cited by 1,937
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W., Grothey, A., Vauthey, J.-N., Nagorney, D. M., & McWilliams, R. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5278 · Cited by 1,339
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Kennedy, A., Nag, S., Salem, R., Murthy, R., McEwan, A. J., Nutting, C., Benson, A., Espat, J., Bilbao, J. I., Sharma, R. A., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.060 · Cited by 676
Gray, B., Van Hazel, G., Hope, M., Burton, M., Moroz, P., Anderson, J., & Gebski, V. (2001) · Annals of Oncology · doi:10.1023/a:1013569329846 · Cited by 526
van Hazel, G., Blackwell, A., Anderson, J., Price, D., Moroz, P., Bower, G., CARDACI, G. T., & Gray, B. N. (2004) · Journal of Surgical Oncology · doi:10.1002/jso.20141 · Cited by 442
Kennedy, A. S., Nutting, C., Coldwell, D., Gaiser, J., & Drachenberg, C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.004 · Cited by 407
Kennedy, A. S., Coldwell, D., Nutting, C., Murthy, R., Wertman, D. E., Loehr, S. P., Overton, C., Meranze, S., Niedzwiecki, J., & Sailer, S. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.12.051 · Cited by 375
Sharma, R. A., Hazel, G. A. V., Morgan, B., Berry, D. P., Blanshard, K., Price, D., Bower, G., Shannon, J. A., Gibbs, P., & Steward, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.7916 · Cited by 323
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D., & Vauthey, J.-N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 173
Wong, C.-Y., Salem, R., Raman, S., Gates, V. L., & Dworkin, H. J. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0787-4 · Cited by 162
Hazel, G. A. V., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M. J., Price, D., Bower, G., Briggs, G. M., Rossleigh, M. A., Taylor, D. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8116 · Cited by 153
Hepatic Yttrium-90 Radioembolization of Chemotherapy-refractory Colorectal Cancer Liver Metastases
Jakobs, T. F., Hoffmann, R., Dehm, K., Trumm, C., Stemmler, H., Tatsch, K., la Fougère, C., Murthy, R., Helmberger, T. K., & Reiser, M. F. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2008.05.013 · Cited by 143
Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy
Campbell, A. M., Bailey, I. H., & Burton, M. A. (2001) · Physics in Medicine and Biology · doi:10.1088/0031-9155/46/2/315 · Cited by 122
Modern multimodality approach to hepatic colorectal metastases: Solutions and controversies
Khatri, V. P., Chee, K. G., & Petrelli, N. J. (2007) · Surgical Oncology · doi:10.1016/j.suronc.2007.05.001 · Cited by 77
Lau, W. Y., Leung, T. W. T., Ho, S., Chan, M., Leung, N. W. Y., Lin, J., Metreweli, C., & Li, A. K. C. (1994) · British Journal of Radiology · doi:10.1259/0007-1285-67-794-136 · Cited by 42
Sharma, R. A., Wasan, H. S., Love, S., Dutton, S., Stokes, J. C., & Smith, J. (2008) · Clinical Oncology · doi:10.1016/j.clon.2007.12.008 · Cited by 35
Stuart, J. E., Tan, B. R., Myerson, R. J., Garcia-Ramirez, J. L., Goddu, S. M., Pilgram, T. K., & Brown, D. B. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2008.07.009 · Cited by 35
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J., Peeters, M., Findlay, M., Weaver, A., Mills, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30457-6 · Cited by 403
Self-citationPrognostic factors and prevention of radioembolization-induced liver disease
Gil-Alzugaray, B., Chopitea, A., Iñarrairaegui, M., Bilbao, J. I., Rodriguez-Fraile, M., Rodriguez, J., Benito, A., Dominguez, I., D'Avola, D., Herrero, J. I., et al. (2013) · Hepatology · doi:10.1002/hep.26191 · Cited by 275
Metadata
- Authors
- Hendlisz, A., Eynde, M. V. D., Peeters, M., Maleux, G., Lambert, B., Vannoote, J., Keukeleire, K. D., Verslype, C., Defreyne, L., Cutsem, E. V., Delatte, P., Delaunoit, T., Personeni, N., Paesmans, M., Laethem, J.-L. V., & Flamen, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-10
- Volume
- 28
- Issue
- 23
- Pages
- 3687-3694
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116960604
- Cited by
- 408
- References
- 31
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.